Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer (CRTCOESC)
Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer
Sponsor: Anyang Cancer Hospital
This PHASE3 trial investigates Stage II Esophageal Squamous Cell Carcinoma and Stage III Esophageal Squamous Cell Carcinoma and is currently ongoing. Anyang Cancer Hospital leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
May 2025 — Present [monthly]
Unknown PHASE3
Status: Active Not Recruiting → Unknown
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Mar 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
May 2022 — Mar 2023 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Jan 2021 — May 2022 [monthly]
Active Not Recruiting PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Nov 2019 — Jun 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — Nov 2019 [monthly]
Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anyang Cancer Hospital
- Henan Oncology Hospital
- Luoyang Central Hospital
- Military 150 Hospital
- Nanyang Central Hospital
- Sanmenxia Central Hospital
- The First Affiliated Hospital of Henan University of Science and Technology
- The First Affiliated Hospital of Xinyang Medical College
For direct contact, visit the study record on ClinicalTrials.gov .